PURPOSE: To examine the patterns of failure in patients treated with intensity-modulated radiotherapy (IMRT) for head-and-neck rhabdomyosarcoma (RMS). METHODS AND MATERIALS: Between 1998 and 2005, 19 patients with a diagnosis of head-and-neck RMS received IMRT at The Methodist Hospital. There were 11 male and 8 female patients, with a median age of 6 years at time of irradiation. Tumor location was parameningeal in 7, orbital in 6, and other head-and-neck RMS in 6. Chemotherapy was given to all patients, with vincristine, actinomycin D, and cyclophosphamide being the most common regimen (n = 18). The median prescribed dose was 5040 cGy. The clinical target volume included the gross tumor volume with a 1.5-cm margin. The median duration of follow-up for surviving patients was 56 months. RESULTS: The 4-year overall survival and local control rates were 76% and 92.9%, respectively. One patient developed a local failure in the high-dose region of the radiation field; there were no marginal failures. Distant metastasis was seen in 4 patients. Overall survival was 42.9% for parameningeal sites and 100% for other sites (p < 0.01). Late toxicities were seen in 7 patients. Two secondary malignancies occurred in 1 child with embryonal RMS of the face and a p53 mutation. CONCLUSIONS: Local control was excellent in patients receiving IMRT for head-and-neck RMS. Patterns of local failure reveal no marginal failures in this group of patients.
PURPOSE: To examine the patterns of failure in patients treated with intensity-modulated radiotherapy (IMRT) for head-and-neck rhabdomyosarcoma (RMS). METHODS AND MATERIALS: Between 1998 and 2005, 19 patients with a diagnosis of head-and-neck RMS received IMRT at The Methodist Hospital. There were 11 male and 8 female patients, with a median age of 6 years at time of irradiation. Tumor location was parameningeal in 7, orbital in 6, and other head-and-neck RMS in 6. Chemotherapy was given to all patients, with vincristine, actinomycin D, and cyclophosphamide being the most common regimen (n = 18). The median prescribed dose was 5040 cGy. The clinical target volume included the gross tumor volume with a 1.5-cm margin. The median duration of follow-up for surviving patients was 56 months. RESULTS: The 4-year overall survival and local control rates were 76% and 92.9%, respectively. One patient developed a local failure in the high-dose region of the radiation field; there were no marginal failures. Distant metastasis was seen in 4 patients. Overall survival was 42.9% for parameningeal sites and 100% for other sites (p < 0.01). Late toxicities were seen in 7 patients. Two secondary malignancies occurred in 1 child with embryonal RMS of the face and a p53 mutation. CONCLUSIONS: Local control was excellent in patients receiving IMRT for head-and-neck RMS. Patterns of local failure reveal no marginal failures in this group of patients.
Authors: Matthew M Ladra; Jackie D Szymonifka; Anita Mahajan; Alison M Friedmann; Beow Yong Yeap; Claire P Goebel; Shannon M MacDonald; David R Grosshans; Carlos Rodriguez-Galindo; Karen J Marcus; Nancy J Tarbell; Torunn I Yock Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Stephanie K Childs; Kevin R Kozak; Alison M Friedmann; Beow Y Yeap; Judith Adams; Shannon M MacDonald; Norbert J Liebsch; Nancy J Tarbell; Torunn I Yock Journal: Int J Radiat Oncol Biol Phys Date: 2011-03-04 Impact factor: 7.038
Authors: Pierre Heudel; Marie Claude Biston; Jérome Fayette; Antoine Ramade; Frédéric Gassa; Pascal Pommier Journal: Int J Clin Oncol Date: 2010-03-02 Impact factor: 3.402
Authors: Chi Lin; Sarah S Donaldson; Jane L Meza; James R Anderson; Elizabeth R Lyden; Christopher K Brown; Karen Morano; Fran Laurie; Carola A Arndt; Charles A Enke; John C Breneman Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-04 Impact factor: 7.038
Authors: Rainer Joachim Strege; György Kovács; Jens Eduard Meyer; Detlef Holland; Alexander Claviez; Maximilian H Mehdorn Journal: Strahlenther Onkol Date: 2009-12 Impact factor: 3.621
Authors: Natalie A Lockney; Danielle Novetsky Friedman; Leonard H Wexler; Charles A Sklar; Dana L Casey; Suzanne L Wolden Journal: Pediatr Blood Cancer Date: 2016-05-16 Impact factor: 3.167
Authors: Florian Sterzing; Eva M Stoiber; Simeon Nill; Harald Bauer; Peter Huber; Jürgen Debus; Marc W Münter Journal: Radiat Oncol Date: 2009-09-23 Impact factor: 3.481